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BackgroundTo compare the efficacy and safety of pharmacokinetically (PK) guided
fluorouracil (5-FU) dose adjustment vs. standard body-surface-area (BSA) dosing in
a FOLFOX (folinic acid, fluorouracil, oxaliplatin) regimen in metastatic colorectal
cancer (mCRC). Patients And Methods A total of 118 patients with mCRC were
administered individually determined PK-adjusted 5-FU in first-line FOLFOX
chemotherapy. The comparison arm consisted of 39 patients, and these patients
were also treated with FOLFOX with 5-FU by BSA. For the PK-adjusted arm 5-FU
was monitored during infusion, and the dose for the next cycle was based on a dose-
adjustment chart to achieve a therapeutic area under curve range (5-FUODPM
Protocol). Results The objective response rate was 69.7% in the PK-adjusted arm,
and median overall survival and median progression-free survival were 28 and 16
months, respectively. In the traditional patients who received BSA dosage, objective
response rate was 46%, and overall survival and progression-free survival were 22
and 10 months, respectively. Grade 3/4 toxicity was 1.7% for diarrhea, 0.8% for
mucositis, and 18% for neutropenia in the dose-monitored group; they were 12%,
15%, and 25%, respectively, in the BSA group. Conclusions Efficacy and tolerability
of PK-adjusted FOLFOX dosing was much higher than traditional BSA dosing in
agreement with previous reports for 5-FU monotherapy PK-adjusted dosing. Analysis
of these results suggests that PK-guided 5-FU therapy offers added value to
combination therapy for mCRC.
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